Evidence map›Paper›PMID 31795176›Full record

ArticleBiomolecules2019

Evaluation of Human Cerebrospinal Fluid Malate Dehydrogenase 1 as a Marker in Genetic Prion Disease Patients.

Inga Zerr, Anna Villar-Piqué, Vanda Edit Schmitz, Anna Poleggi, Maurizio Pocchiari, Raquel Sánchez-Valle, Miguel Calero, Olga Calero, Inês Baldeiras, Isabel Santana and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 16 citations in OpenAlex.

  1. Insights into the Diagnosis, Treatment, and Management of Prion Diseases.CNS & neurological disorders drug targets · 2026
    Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 6 countries.

Inga ZerrDepartment of Neurology, National Reference Center for CJD Surveillance University Medical Center Göttingen, 37075 Göttingen, Germany.ORCID 0000-0002-6722-2463
Anna Villar-PiquéBellvitge Biomedical Research Institute (IDIBELL), 08908 Hospitalet de Llobregat, Spain.
Vanda Edit SchmitzDepartment of Neurology, National Reference Center for CJD Surveillance University Medical Center Göttingen, 37075 Göttingen, Germany.
Anna PoleggiDepartment of Neurosciences, Istituto Superiore di Sanità, 00161 Rome, Italy.ORCID 0000-0001-7094-7767
Maurizio PocchiariDepartment of Neurosciences, Istituto Superiore di Sanità, 00161 Rome, Italy.ORCID 0000-0002-7269-2486
Raquel Sánchez-ValleAlzheimer's Disease and Other Cognitive Disorders Unit, Neurology Department, Hospital Clinic, IDIBAPS, 08036 Barcelona, Spain.
Miguel CaleroNetwork Center for Biomedical Research in Neurodegenerative Diseases, (CIBERNED), Instituto de Salud Carlos III, 28031 Madrid, Spain.ORCID 0000-0001-5366-3324
Olga CaleroNetwork Center for Biomedical Research in Neurodegenerative Diseases, (CIBERNED), Instituto de Salud Carlos III, 28031 Madrid, Spain.
Inês BaldeirasCenter for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal. Faculty of Medicine, University of Coimbra, 3004-517 Coimbra, Portugal.
Isabel SantanaCenter for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal. Faculty of Medicine, University of Coimbra, 3004-517 Coimbra, Portugal.
Gabor G KovacsInstitute of Neurology, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0003-3841-5511
Franc LlorensDepartment of Neurology, National Reference Center for CJD Surveillance University Medical Center Göttingen, 37075 Göttingen, Germany.ORCID 0000-0002-9756-7497
Matthias SchmitzDepartment of Neurology, National Reference Center for CJD Surveillance University Medical Center Göttingen, 37075 Göttingen, Germany.ORCID 0000-0002-5502-681X
Instituto de Salud Carlos III · ESGerman Center for Neurodegenerative Diseases · DEHospitais da Universidade de Coimbra · PTIstituto Superiore di Sanità · ITHospital Clínic de Barcelona · ESUniversitätsmedizin Göttingen · DEUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The exploration of accurate diagnostic markers for differential diagnosis of neurodegenerative diseases is an ongoing topic. A previous study on cerebrospinal fluid (CSF)-mitochondrial malate dehydrogenase 1 (MDH1) in sporadic Creutzfeldt-Jakob disease (sCJD) patients revealed a highly significant upregulation of MDH1. Here, we measured the CSF levels of MDH1 via enzyme-linked immunosorbent assay in a cohort of rare genetic prion disease cases, such as genetic CJD (gCJD) cases, exhibiting the E200K, V210I, P102L (Gerstmann-Sträussler-Scheinker syndrome (GSS)), or D178N (fatal familial insomnia (FFI)) mutations in the

Indexed as

14-3-3 ProteinsAdultAgedBiomarkersFemaleHumansMalate DehydrogenaseMaleMiddle AgedPrion Diseasestau ProteinsUp-Regulation14-3-3 ProteinsBiomarkersMalate Dehydrogenasetau Proteinscerebrospinal fluiddiagnostic biomarkergenetic prion diseasesmitochondrial malate dehydrogenase 1PRNP codon 129 MV genotypes

Identifiers

PMID31795176
PMCPMC6995564
OpenAlexW2991578247

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.